astrazeneca, Cancer, epidermalgrowthfactorreceptor, gefitinib, health2cmedical2cpharma, lungcancer, nathanpennell, neoplasms, non small celllungcarcinoma, oncology, organiccompounds, osimertinib, small cellcarcinoma, t790m, Tech Industry, Tech News
Lung Cancer Pill Cuts Risk of Dying by Half in Major Trial
A pill for lung cancer has delivered impressive results in newly published research over the weekend. The pill, called osimertinib, was found to cut the risk of dying in half over a five-year span in those who received it alongside surgery. The treatme…
